Montag A & Associates Inc. Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Montag A & Associates Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,769 shares of the biopharmaceutical company’s stock after selling 2,430 shares during the period. Montag A & Associates Inc.’s holdings in Pfizer were worth $3,247,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the 3rd quarter valued at about $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the 3rd quarter valued at approximately $34,000. VisionPoint Advisory Group LLC raised its position in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on PFE shares. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Morgan Stanley upped their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $36.00.

Pfizer Price Performance

NYSE:PFE traded down $0.07 during midday trading on Thursday, hitting $28.20. 47,806,405 shares of the stock were exchanged, compared to its average volume of 43,591,230. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average price of $26.94 and a two-hundred day moving average price of $28.12. The company has a market capitalization of $159.66 billion, a price-to-earnings ratio of -469.59, a P/E/G ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the company earned $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.96%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.